Research Analysts Issue Forecasts for Humacyte Q3 Earnings

Humacyte, Inc. (NASDAQ:HUMA) – Stock analysts at HC Wainwright issued their Q3 2025 earnings per share (EPS) estimates for Humacyte in a research note issued on Wednesday, May 14th. HC Wainwright analyst S. Ramakanth anticipates that the company will earn ($0.13) per share for the quarter. HC Wainwright has a “Buy” rating and a $4.00 price target on the stock. The consensus estimate for Humacyte’s current full-year earnings is ($1.27) per share. HC Wainwright also issued estimates for Humacyte’s Q4 2025 earnings at ($0.12) EPS, FY2025 earnings at ($0.53) EPS, FY2026 earnings at ($0.42) EPS, FY2027 earnings at ($0.23) EPS, FY2028 earnings at $0.13 EPS and FY2029 earnings at $0.39 EPS.

Several other equities research analysts have also recently weighed in on HUMA. D. Boral Capital reaffirmed a “buy” rating and issued a $25.00 price target on shares of Humacyte in a research report on Tuesday, May 13th. Benchmark reduced their price objective on shares of Humacyte from $17.00 to $14.00 and set a “buy” rating for the company in a research note on Wednesday, May 14th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $11.71.

Humacyte Price Performance

Shares of Humacyte stock opened at $2.49 on Monday. The stock has a market cap of $386.25 million, a price-to-earnings ratio of -1.86 and a beta of 1.64. The firm’s 50-day moving average is $1.81 and its two-hundred day moving average is $3.44. Humacyte has a 1 year low of $1.15 and a 1 year high of $9.97.

Humacyte (NASDAQ:HUMA) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.09. The firm had revenue of $0.52 million for the quarter, compared to the consensus estimate of $0.46 million.

Insider Transactions at Humacyte

In other news, CFO Dale A. Sander bought 20,000 shares of the stock in a transaction on Thursday, April 10th. The stock was bought at an average cost of $1.53 per share, for a total transaction of $30,600.00. Following the completion of the purchase, the chief financial officer now directly owns 40,600 shares in the company, valued at approximately $62,118. The trade was a 97.09% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Kathleen Sebelius purchased 50,000 shares of the business’s stock in a transaction on Tuesday, April 8th. The stock was purchased at an average cost of $1.32 per share, for a total transaction of $66,000.00. Following the completion of the acquisition, the director now directly owns 91,207 shares of the company’s stock, valued at approximately $120,393.24. The trade was a 121.34% increase in their position. The disclosure for this purchase can be found here. Insiders have bought a total of 83,993 shares of company stock valued at $118,224 in the last 90 days. Insiders own 5.10% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in HUMA. Heights Capital Management Inc. acquired a new stake in Humacyte in the first quarter worth about $6,863,000. RA Capital Management L.P. purchased a new position in shares of Humacyte in the 1st quarter valued at approximately $5,648,000. Woodline Partners LP boosted its stake in Humacyte by 235.7% in the 4th quarter. Woodline Partners LP now owns 2,848,802 shares of the company’s stock worth $14,386,000 after purchasing an additional 2,000,268 shares in the last quarter. Monashee Investment Management LLC purchased a new stake in Humacyte during the 1st quarter worth approximately $3,410,000. Finally, CenterBook Partners LP acquired a new position in Humacyte during the 4th quarter valued at approximately $6,463,000. 44.71% of the stock is owned by institutional investors and hedge funds.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.